The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans

Journal of Clinical Investigation

Volumn 119, Issue 10, 2009, Pages 3011-3023

  Charles, Kellie A ^a,e   Kulbe, Hagen ^a   Soper, Robin ^a   Escorcio Correia, Monica ^a   Lawrence, Toby ^a   Schultheis, Anne ^a   Chakravarty, Probir ^b   Thompson, Richard G ^a   Kollias, George ^c   Smyth, John F ^d   Balkwill, Frances R ^a   Hagemann, Thorsten ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; NEUTRALIZING ANTIBODY; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; BONE MARROW CELL; CANCER GROWTH; CANCER MODEL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MICROENVIRONMENT; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TH17 CELL; TUMOR BIOPSY; TUMOR PROMOTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CHIMERA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-23; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349668946     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39065     Document Type: Article

References (71)

1. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. 2008. Cancer-related inflammation. Nature. 454:436-444.
2. McInnes, I.B., and Schett, G. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7:429-442.
3. Balkwill, F. 2006. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25:409-416.
4. Hodge, D.R., Hurt, E.M., and Farrar, W.L. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer. 41:2502-2512.
5. Naugler, W.E., et al. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121-124.
6. Numasaki, M., et al. 2003. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620-2627. (Pubitemid 36857622)
7. Langowski, J.L., et al. 2006. IL-23 promotes tumour incidence and growth. Nature. 442:461-465.
8. Sredni, B., et al. 2004. Ammonium trichloro-(dioxoethylene- o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 64:1843-1852. (Pubitemid 38428710)
9. Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117-129. (Pubitemid 32952643)
10. Feldmann, M., and Maini, S.R. 2008. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 223:7-19. (Pubitemid 351986171)
11. Moore, R.J., et al. 1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5:828-831.
12. Pikarsky, E., et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466. (Pubitemid 39329586)
13. Popivanova, B.K., et al. 2008. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118:560-570.
14. Egberts, J.H., et al. 2008. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68:1443-1450.
15. Yang, H., et al. 2006. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl. Acad. Sci. U. S. A. 103:10397-10402. (Pubitemid 44051178)
16. Balkwill, F. 2009. Tumor necrosis factor and cancer. Nat. Rev. Cancer. 9:361-371.
17. Davies, B., et al. 1993. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer. 67:1126-1131. (Pubitemid 23147516)
18. Harrison, M.L., et al. 2007. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25:4542-4549.
19. Galban, S., et al. 2003. von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol. Cell. Biol. 23:2316-2328. (Pubitemid 36351015)
20. Kulbe, H., et al. 2007. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67:585-592. (Pubitemid 46192196)
21. Stathopoulos, G.T., et al. 2007. Tumor necrosis factor- a promotes malignant pleural effusion. Cancer Res. 67:9825-9834.
22. Petersen, S.L., et al. 2007. Autocrine TNFa signaling renders human cancer cells susceptible to Smac-mimetic- induced apoptosis. Cancer Cell. 12:445-456.
23. Zins, K., Abraham, D., Sioud, M., and Aharinejad, S. 2007. Colon cancer cell-derived tumor necrosis factor-a mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res. 67:1038-1045. (Pubitemid 46270759)
24. Bates, R.C., and Mercurio, A.M. 2003. Tumor necrosis factor-α stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell. 14:1790-1800. (Pubitemid 36583533)
25. Yan, B., et al. 2006. Tumor necrosis factor-a is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 66:11565-11570. (Pubitemid 46094163)
26. Li, B., et al. 2009. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 69:338-348.
27. Elgert, K.D., Alleva, D.G., and Mullins, D.W. 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64:275-290.
28. Hagemann, T., et al. 2008. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205:1261-1268. (Pubitemid 351831483)
29. Tomita, Y., et al. 2004. Spontaneous regression of lung metastasis in the absence of tumor necrosis factor receptor p55. Int. J. Cancer. 112:927-933. (Pubitemid 39506997)
30. Kitakata, H., et al. 2002. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 62:6682-6687. (Pubitemid 35364138)
31. Arnott, C.H., et al. 2004. Expression of both TNFalpha receptor subtypes is essential for optimal skin tumour development. Oncogene. 23:1902-1910.
32. Chen, X., Baumel, M., Mannel, D.N., Howard, O.M., and Oppenheim, J.J. 2007. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179:154-161. (Pubitemid 46986529)
33. Scott, K.A., et al. 2003. An anti-tumor necrosis factoralpha antibody inhibits the development of experimental skin tumors. Mol. Cancer Ther. 2:445-451.
34. Madhusudan, S., et al. 2004. A phase II study of Etanercept (Enbrel), a tumour necrosis factor-a inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10:6528-6534. (Pubitemid 39346547)
35. Madhusudan, S., et al. 2004. A phase II study of etanercept (ENBREL), a tumor necrosis factor-alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10:6528-6534. (Pubitemid 39346547)
36. Brown, E.R., et al. 2008. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 19:1340-1346.
37. Victoratos, P., et al. 2006. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity. 24:65-77. (Pubitemid 43077201)
38. Moseley, T.A., Haudenschild, D.R., Rose, L., and Reddi, A.H. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14:155-174.
39. Witowski, J., et al. 2000. IL-17 stimulates intra-peritoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J. Immunol. 165:5814-5821. (Pubitemid 30838117)
40. Bettelli, E., Korn, T., Oukka, M., and Kuchroo, V.K. 2008. Induction and effector functions of T(H)17 cells. Nature. 453:1051-1057. (Pubitemid 351871737)
41. Bettelli, E., Oukka, M., and Kuchroo, V.K. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345-350.
42. Kolls, J.K., and Linden, A. 2004. Interleukin-17 family members and inflammation. Immunity. 21:467-476.
43. Fossiez, F., et al. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183:2593-2603. (Pubitemid 26193037)
44. Kryczek, I., et al. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178:6730-6733. (Pubitemid 46847396)
45. Liu, S.J., et al. 2007. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J. Leukoc. Biol. 82:354-360.
46. Laan, M., et al. 1999. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162:2347-2352. (Pubitemid 29288861)
47. Rodriguez, N., et al. 2005. Polymorphonuclear neutrophils improve replication of Chlamydia pneumoniae in vivo upon MyD88-dependent attraction. J. Immunol. 174:4836-4844. (Pubitemid 40504567)
48. Robben, P.M., LaRegina, M., Kuziel, W.A., and Sibley, L.D. 2005. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. J. Exp. Med. 201:1761-1769. (Pubitemid 41002895)
49. Miyahara, Y., et al. 2008. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 105:15505-15510.
50. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stockinger, B. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179-189. (Pubitemid 43214587)
51. Sutton, C., Brereton, C., Keogh, B., Mills, K.H., and Lavelle, E.C. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203:1685-1691. (Pubitemid 44036274)
52. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney, A.L. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278:1910-1914. (Pubitemid 36801431)
53. van Beelen, A.J., et al. 2007. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 27:660-669.
54. Wilson, N.J., et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8:950-957. (Pubitemid 47300009)
55. Charles, P., et al. 1999. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163:1521-1528. (Pubitemid 29352775)
56. Baert, F., et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348:601-608. (Pubitemid 36204954)
57. Maini, R.N., and Taylor, P.C. 2000. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51:207-229.
58. Notley, C.A., et al. 2008. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J. Exp. Med. 205:2491-2497.
59. Balkwill, F. 2009. Tumour necrosis factor and cancer. Nat. Rev. Cancer. 9:361-371.
60. Calzascia, T., et al. 2007. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117:3833-3845. (Pubitemid 350224093)
61. Dranoff, G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer. 4:11-22.
62. Askling, J., and Bongartz, T. 2008. Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20:334-339.
63. Kuprash, D.V., et al. 2008. Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice. Cancer Lett. 268:70-75.
64. Grivennikov, S.I., et al. 2005. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity. 22:93-104.
65. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8:265-277. (Pubitemid 29523965)
66. Roby, K.F., et al. 2000. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 21:585-591.
67. Hagemann, T., et al. 2006. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176:5023-5032.
68. Acosta-Rodriguez, E.V., et al. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639-646.
69. Gentleman, R.C., et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80.
70. Gautier, L., Cope, L., Bolstad, B.M., and Irizarry, R.A. 2004. affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307-315. (Pubitemid 38262761)
71. Smyth, G.K. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:Article3.